Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | PDE4A | P27815 | 6/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 4/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | PTAFR | P25105 | 2/20 | 0.32 |
| ▸ | RARB | P10826 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22459276 | 0.92 | EGFR (0.41) | EGFRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22459876 | 0.89 | EGFR (0.39) | EGFRPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22459716 | 0.89 | PDE4A (0.36) | PDE4APDE4BPDE4CPDE4DTNKS2 | |
| SCHEMBL22459808 | 0.88 | TNKS2 (0.42) | TNKS2METAKR1B10AKR1B1ALOX5 | |
| SCHEMBL22561079 | 0.88 | LPAR1 (0.33) | PDE4APDE4BPDE4CPDE4DTNKS2 | |
| SCHEMBL22082240 | 0.87 | RARB (0.38) | PDE4APDE4BPDE4CPDE4DRARB | |
| SCHEMBL22459252 | 0.87 | LMNA (0.40) | METAKR1B10AKR1B1RARBLMNA | |
| SCHEMBL22459412 | 0.87 | LMNA (0.40) | METAKR1B10AKR1B1RARBLMNA | |
| SCHEMBL22459840 | 0.87 | RARB (0.34) | PDE4APDE4BPDE4CPDE4DMET | |
| SCHEMBL22459611 | 0.87 | RARB (0.43) | RARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725764-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC Corporation (JP) | 2020-10-21 | — | — | EP | disclosed |
| US-20200299578-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299578-A1 | POLYMERIZABLE COMPOUND HAVING METHOXYMETHYL ACRYLIC GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, CCND1, CPNE4 | EGFR 2937/4885PDE4A 4002/4885PDE4B 4162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.